Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829039 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10NPC1LMNA | |
| SCHEMBL569988 | 0.86 | KDM4E (0.70) | KDM4EALDH1A1HSD17B10LMNAMAPT | |
| SCHEMBL6506620 | 0.85 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10NPC1LMNA | |
| SCHEMBL12495433 | 0.84 | ALDH1A1 (0.72) | KDM4EALDH1A1HSD17B10NPC1LMNA | |
| SCHEMBL5121884 | 0.82 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10NPC1LMNA | |
| SCHEMBL15643239 | 0.82 | TSPO (0.58) | KDM4EALDH1A1HSD17B10NPC1LMNA | |
| SCHEMBL4288066 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1HSD17B10LMNAKMT2A | |
| SCHEMBL3580770 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1HSD17B10NPC1LMNA | |
| SCHEMBL15643536 | 0.81 | MAPT (0.65) | KDM4EALDH1A1HSD17B10NPC1LMNA | |
| SCHEMBL17824310 | 0.80 | LMNA (0.53) | KDM4EALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2006049681-A2 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | KDM4E 2974/4885ALDH1A1 2368/4885HSD17B10 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.